Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Long-acting HIV shot study aims to make prevention fairer for all

NCT ID NCT07620730

Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a long-acting injectable HIV prevention drug (cabotegravir) can be delivered fairly and effectively in NHS sexual health clinics. Researchers will follow 200 people taking the drug for 12 months, along with 20 healthcare professionals, to see how well it works in real-world settings and whether it reaches groups often underserved by current prevention options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
long-acting cabotegravir (LA CAB)
What this could lead to
If successful, this could show that long-acting injectable PrEP is a practical and equitable option for HIV prevention in the NHS, especially for underserved groups.
What could go wrong
This is an implementation study, not a test of the drug itself. It may reveal barriers that limit uptake or persistence, and results may not apply outside the UK.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The participants in this study are 1) PrEP users and 2) NHS healthcare providers (HCPs) recruited from 12 study sites (sexual health clinics and associated non-specialist service delivery sites) that currently deliver PrEP. HCP participants will include doctors, nurses and pharmacists who currently provide injectable PrEP. Note: PrEP user participants are those who are both naive (new to ) to any PrEP modality, and PrEP experienced (former or current oral and/ or injectable PrEP users), on PrEP in accordance with NHS and NICE guidelines (28).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants of any gender, ethnicity or socio-economic group who meet all the following criteria are eligible for inclusion in this study: * Adults who are aged \> 18 years at time of consent (including people of child-bearing capacity and age, non-pregnant or pregnant adults) * Attending a participating NHS sexual healthcare service * Prescribed LA CAB for PrEP according to NICE and NHS eligibility criteria (including those newly prescribed and those already using LA CAB) * Non-reactive / negative HIV Antigen/Antibody test and HIV RNA test at time of LA CAB for PrEP initiation (performed under routine care) * Able and willing and able to give informed consent to all study procedures prior to inclusion Exclusion Criteria: PrEP user participants who meet any of the following criteria are ineligible for inclusion in this study: * One or more reactive or positive HIV test results at enrolment visit, even if HIV infection is not confirmed. * Currently enrolled in interventional trial of PrEP agents, HIV vaccine trial or experimental medication. * Plan to relocate out of the area during the study period. Note: "Plan to relocate out of the area" is defined as a stated intention at enrolment to move residence outside the catchment area of a participating study site during the study period, such that ongoing clinical management would likely transfer to a non-participating team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community setting are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

posterior leukoencephalopathy syndrome HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Community setting EQUITY PREP Prep adherence experiences Prep adherence perspectives Prep uptake

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.